Background: Helicobacter pylori has been shown to be a key contributor to chronic gastritis. Peptic ulcer disease, gastric adenocarcinoma, and gastric lymphoma are all linked to this condition, which affects 50% of the world's population. Vitamin D therapy was used in this research to show that helicobacter pylori infection may be eliminated with treatment. Methods: A total of 50 Egyptian patients with dyspeptic symptoms lasting at least one month were involved in this case study. Between April 2021 and July 2021, patients were recruited from the Benha University Hospital in Benha, Egypt (including inpatients and outpatients). The participants in this research were 50 Egyptians with a history of dyspepsia. Patients were categorised into two groups: Group A: 25 patients with helicobacter pylori infection who received clarithromycin-based triple treatment and a vitamin D supplement were included. 25 individuals with Helicobacter pylori infection received triple clarithromycin treatment without vitamin D supplementation in group B. Results: There was a statistically significant difference (p= 0.031) in the efficacy of vitamin D between the two groups, with 84% of patients in group A showing favourable outcomes whereas only 56% of the patients in group B exhibited positive results. Conclusion: As a result, supplementing Clarithromycin-based Triple Therapy with vitamin D3 may increase eradication rates for H. pylori infections substantially.